Gupta, P., Mulkey, F., Hasserjian, R. P., Sanford, B. L., Vij, R., Hurd, D. D., . . . Larson, R. A. (2013). A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance).
Chicago Stili AlıntıGupta, Pankaj, et al. A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance). 2013.
MLA AlıntıGupta, Pankaj, et al. A Phase II Study of the Oral VEGF Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787/ZK222584) in Myelodysplastic Syndrome: Cancer and Leukemia Group B Study 10105 (Alliance). 2013.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..